News
The Committee discusses and makes recommendations for AstraZeneca (AZN) supplemental Biologics License Application (sBLA) 125586/546 for Andexxa (coagulation factor Xa (recombinant), inactivated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback